Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024.

Fireside Chat detailsDate: Wednesday, June 5, 2024 Time: 1:00 – 1:25 PM ETWebcast Link: https://wsw.com/jefferieswebcast/cmpx/

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.

About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact[email protected]

Media ContactAnna Gifford, Senior Communications Manager[email protected]617-500-8099

You May Also Be Interested In

• IBA joins PFAROS European initiative to advance PFAS destruction for healthcare and pharmaceutical applications
• PROCEPT BioRobotics Corporation Securities Fraud Class Action Result of Undisclosed Inventory Issues and approximately 18% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti,
• HDFC Bank Limited Securities Fraud Class Action Result of Deceptive Interest Payments and Approximately 4% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC